Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and raises the price target from $220 to $234.
Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and raises the price target from $220 to $234.